360 related articles for article (PubMed ID: 17284626)
1. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty.
van Gool SA; Kamp GA; Visser-van Balen H; Mul D; Waelkens JJ; Jansen M; Verhoeven-Wind L; Delemarre-van de Waal HA; de Muinck Keizer-Schrama SM; Leusink G; Roos JC; Wit JM
J Clin Endocrinol Metab; 2007 Apr; 92(4):1402-8. PubMed ID: 17284626
[TBL] [Abstract][Full Text] [Related]
2. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
Pasquino AM; Pucarelli I; Roggini M; Segni M
J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
[TBL] [Abstract][Full Text] [Related]
3. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
Pasquino AM; Municchi G; Pucarelli I; Segni M; Mancini MA; Troiani S
J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
[TBL] [Abstract][Full Text] [Related]
6. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment.
Lem AJ; van der Kaay DC; Hokken-Koelega AC
J Clin Endocrinol Metab; 2013 Jan; 98(1):77-86. PubMed ID: 23125290
[TBL] [Abstract][Full Text] [Related]
8. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
Massart F; Federico G; Harrell JC; Saggese G
Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
[TBL] [Abstract][Full Text] [Related]
9. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
Léger J; Reynaud R; Czernichow P
J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
[TBL] [Abstract][Full Text] [Related]
10. Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone.
Mul D; Oostdijk W; Waelkens JJ; Drop SL
Clin Endocrinol (Oxf); 2005 Aug; 63(2):185-90. PubMed ID: 16060912
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
Heger S; Partsch CJ; Sippell WG
J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
[TBL] [Abstract][Full Text] [Related]
13. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.
Paul D; Conte FA; Grumbach MM; Kaplan SL
J Clin Endocrinol Metab; 1995 Feb; 80(2):546-51. PubMed ID: 7852518
[TBL] [Abstract][Full Text] [Related]
15. Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience.
Kohn B; Julius JR; Blethen SL
Pediatrics; 1999 Oct; 104(4 Pt 2):1014-8. PubMed ID: 10506254
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
[TBL] [Abstract][Full Text] [Related]
17. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature.
Yanovski JA; Rose SR; Municchi G; Pescovitz OH; Hill SC; Cassorla FG; Cutler GB
N Engl J Med; 2003 Mar; 348(10):908-17. PubMed ID: 12621135
[TBL] [Abstract][Full Text] [Related]
18. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial.
Lem AJ; van der Kaay DC; de Ridder MA; Bakker-van Waarde WM; van der Hulst FJ; Mulder JC; Noordam C; Odink RJ; Oostdijk W; Schroor EJ; Sulkers EJ; Westerlaken C; Hokken-Koelega AC
J Clin Endocrinol Metab; 2012 Nov; 97(11):4096-105. PubMed ID: 22904179
[TBL] [Abstract][Full Text] [Related]
19. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.
Mul D; Bertelloni S; Carel JC; Saggese G; Chaussain JL; Oostdijk W
Horm Res; 2002; 58(1):1-7. PubMed ID: 12169774
[TBL] [Abstract][Full Text] [Related]
20. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
Fjellestad-Paulsen A; Simon D; Czernichow P
J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
